Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CABA with free AI briefings, catalyst countdowns, and dilution alerts.

CABA · Cabaletta Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$299.4M Cash on Hand
21.3mo Cash Runway
19.2% Short Interest
$11.75 Analyst Target (8)
Follow CABA by email Get an email when CABA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CABA, unsubscribe in one click. Privacy

📣 What CABA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Autologous Anti-CD19 CAR-T Cells CABA-201 Systemic Sclerosis Phase 2/3 · NCT06328777 Recruiting
Fludarabine Idiopathic Inflammatory Myopathy Phase 2/3 · NCT06154252 Recruiting
Autologous Desmoglein-3 Chimeric Autoantibody… Pemphigus Vulgaris Phase 1/2 · NCT04422912 Recruiting
Autologous MuSK-CD3z/4-1BB-expressing Chimeric… MuSK Myasthenia Gravis Phase 1 · NCT05451212 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CABA holds $299.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $42.1M/quarter from operations, an estimated runway of 21.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CABA files for a raise →

👥 Who Owns CABA

Insiders 0.8% Other 5%+ holders 9.8% Institutions (206 holders) 86.3% Public and other holders 3.1%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 28,138,417 13.04% 2026-10-31
PRUDENTIAL FINANCIAL INC Institution (13G, 5%+) 24,267,980 11.25% 2026-05-31
Jennison Associates LLC Institution (13G, 5%+) 24,267,980 11.25% 2026-05-29
Bain Capital Life Sciences Opportunities 5%+ holder (13G) 21,209,188 9.83% 2026-09-30
Bain Capital Life Sciences Investors, LL Institution (13F) 21,209,188 9.83% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 14,174,758 6.57% 2026-06-30
Adage Capital Partners GP L.L.C. Institution (13F) 14,174,758 6.57% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 13,013,495 6.03% 2026-09-30
State Street Corporation Institution (13F) 8,053,077 3.73% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 7,144,758 3.31% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 6,235,788 2.89% 2026-09-30
Woodline Partners LP Institution (13F) 5,200,642 2.41% 2026-09-30

Share count 215,720,392 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-09
filed 2026-06-10
Brun Scott C.
Option award (A) 22,000 – –
2026-06-09
filed 2026-06-10
Tomasello Shawn
Option award (A) 22,000 – –
2026-06-09
filed 2026-06-10
Simon Mark
Option award (A) 22,000 – –
2026-06-09
filed 2026-06-10
HENRIQUES RICHARD C JR
Option award (A) 22,000 – –
2026-06-09
filed 2026-06-10
Bollard Catherine
Option award (A) 22,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full CABA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CABA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.